 <h1>Elexacaftor / ivacaftor / tezacaftor Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to elexacaftor / ivacaftor / tezacaftor: oral tablet</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, elexacaftor / ivacaftor / tezacaftor may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking elexacaftor / ivacaftor / tezacaftor:</p><p>
<i>Incidence not known</i>
</p><ul>
<li>Abdominal or stomach pain</li>
<li>bloating of the abdomen</li>
<li>dark urine</li>
<li>light-colored stools</li>
<li>nausea and vomiting</li>
<li>yellow eyes or skin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of elexacaftor / ivacaftor / tezacaftor may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Body aches or pain</li>
<li>chills</li>
<li>cough</li>
<li>diarrhea</li>
<li>difficulty in breathing</li>
<li>ear congestion</li>
<li>fever</li>
<li>headache</li>
<li>itching skin or rash</li>
<li>loss of voice</li>
<li>sneezing</li>
<li>sore throat</li>
<li>stuffy or runny nose</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Anxiety</li>
<li>bladder pain</li>
<li>blemishes on the skin</li>
<li>bloated</li>
<li>bloody or cloudy urine</li>
<li>blurred vision</li>
<li>burning, dry, or itching eyes</li>
<li>cold sweats</li>
<li>coma</li>
<li>confusion</li>
<li>cool, pale skin</li>
<li>cramps</li>
<li>depression</li>
<li>difficult, burning, or painful urination</li>
<li>discharge, excessive tearing</li>
<li>dizziness</li>
<li>excess air or gas in the stomach or intestines</li>
<li>fast heartbeat</li>
<li>frequent urge to urinate</li>
<li>full feeling</li>
<li>heavy bleeding</li>
<li>increased hunger</li>
<li>lower back or side pain</li>
<li>nervousness</li>
<li>nightmares</li>
<li>pain</li>
<li>passing gas</li>
<li>pimples</li>
<li>redness, pain, swelling of the eye, eyelid, or inner lining of the eyelid</li>
<li>seizures</li>
<li>shakiness</li>
<li>skin rash, encrusted, scaly, and oozing</li>
<li>slurred speech</li>
</ul><p>
<!-- end oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to elexacaftor / ivacaftor / tezacaftor: oral tablet</i></p><h3>General</h3><p>The most commonly reported adverse reactions have included headache, upper respiratory infection, abdominal pain, diarrhea, rash, and increased ALT levels.<sup>[Ref]</sup></p><h3>Hepatic</h3><p>ALT or AST elevations to greater than 8, 5, or 3 times the upper limit of normal (ULN) occurred in 1%, 2%, and 8% of patients receiving this drug, respectively.  The incidence of maximum total bilirubin elevation greater than 2 x ULN was 4%.  Maximum indirect and direct bilirubin elevations greater than 1.5 x ULN occurred in 11% and 3% of patients, respectively.  No patients experienced a direct bilirubin elevation greater than 2 x ULN.</p><p><b>Very common</b> (10% or more): Increased ALT (10%) </p>
<p><b>Common</b> (1% to 10%): Increased AST, increased bilirubin levels</p><h3>Dermatologic</h3><p>Rash occurred in approximately 10% of patients with a higher incidence in females (16%) compared with males (5%).  It may be that hormonal contraceptive played a role in the occurrence of rash.  If a rash develops while on hormonal contraceptives, consider interrupting both this drug and the hormonal contraceptive.  With resolution of the rash, consider resuming therapy with this drug without the hormonal contraceptive.  If rash does not recur, may consider resuming the hormonal contraceptive.</p><p><b>Common</b> (1% to 10%): Rash, acne, eczema, pruritus</p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (17%)</p>
<p><b>Common</b> (1% to 10%): Dizziness</p><h3>Ocular</h3><p>Elexacaftor / ivacaftor / tezacaftor: </p>
<p><b>Common</b> (1% to 10%): Conjunctivitis</p>
<p></p>
<p>Ivacaftor-Containing Regimens: </p>
<p><b>Frequency not reported</b>: Non-congenital lens opacities/cataracts (pediatric patients)</p><p>Cases of non-congenital lens opacities have been reported in pediatric patients treated with ivacaftor-containing regimens.  Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded.  Findings of cataracts were observed in juvenile rats dosed from postnatal Day 7 through 35 with ivacaftor dose levels of 10 mg/kg/day and higher (0.24 times the MRHD based on systemic exposure of ivacaftor and its metabolites).  This finding has not been observed in older animals.</p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Hypoglycemia</p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Abdominal pain (14%), diarrhea (13%) </p>
<p><b>Common</b> (1% to 10%): Flatulence, abdominal distension</p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Dysmenorrhea, urinary tract infection</p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Influenza</p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Blood creatine phosphokinase increased</p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Elevated blood pressure</p><h3>Other</h3><p><b>Common</b> (1% to 10%): C-reactive protein increased</p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Upper respiratory tract infection (16%) </p>
<p><b>Common</b> (1% to 10%): Nasal congestion, rhinorrhea, rhinitis, sinusitis, pharyngitis, respiratory tract infection, tonsillitis</p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Trikafta (elexacaftor / ivacaftor / tezacaftor)." Vertex Pharmaceuticals, Cambridge, MA. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about elexacaftor / ivacaftor / tezacaftor</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>2 Reviews</li>
<li>Drug class: CFTR combinations</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Elexacaftor, tezacaftor, ivacaftor and ivacaftor &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Trikafta</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Cystic Fibrosis</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to elexacaftor / ivacaftor / tezacaftor: oral tablet</i></p><h3>General</h3><p>The most commonly reported adverse reactions have included headache, upper respiratory infection, abdominal pain, diarrhea, rash, and increased ALT levels.<sup>[Ref]</sup></p><h3>Hepatic</h3><p>ALT or AST elevations to greater than 8, 5, or 3 times the upper limit of normal (ULN) occurred in 1%, 2%, and 8% of patients receiving this drug, respectively.  The incidence of maximum total bilirubin elevation greater than 2 x ULN was 4%.  Maximum indirect and direct bilirubin elevations greater than 1.5 x ULN occurred in 11% and 3% of patients, respectively.  No patients experienced a direct bilirubin elevation greater than 2 x ULN.</p><p><b>Very common</b> (10% or more): Increased ALT (10%) </p><p><b>Common</b> (1% to 10%): Increased AST, increased bilirubin levels</p><h3>Dermatologic</h3><p>Rash occurred in approximately 10% of patients with a higher incidence in females (16%) compared with males (5%).  It may be that hormonal contraceptive played a role in the occurrence of rash.  If a rash develops while on hormonal contraceptives, consider interrupting both this drug and the hormonal contraceptive.  With resolution of the rash, consider resuming therapy with this drug without the hormonal contraceptive.  If rash does not recur, may consider resuming the hormonal contraceptive.</p><p><b>Common</b> (1% to 10%): Rash, acne, eczema, pruritus</p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (17%)</p><p><b>Common</b> (1% to 10%): Dizziness</p><h3>Ocular</h3><p>Elexacaftor / ivacaftor / tezacaftor: </p><p><b>Common</b> (1% to 10%): Conjunctivitis</p><p></p><p>Ivacaftor-Containing Regimens: </p><p><b>Frequency not reported</b>: Non-congenital lens opacities/cataracts (pediatric patients)</p><p>Cases of non-congenital lens opacities have been reported in pediatric patients treated with ivacaftor-containing regimens.  Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded.  Findings of cataracts were observed in juvenile rats dosed from postnatal Day 7 through 35 with ivacaftor dose levels of 10 mg/kg/day and higher (0.24 times the MRHD based on systemic exposure of ivacaftor and its metabolites).  This finding has not been observed in older animals.</p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Hypoglycemia</p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Abdominal pain (14%), diarrhea (13%) </p><p><b>Common</b> (1% to 10%): Flatulence, abdominal distension</p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Dysmenorrhea, urinary tract infection</p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Influenza</p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Blood creatine phosphokinase increased</p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Elevated blood pressure</p><h3>Other</h3><p><b>Common</b> (1% to 10%): C-reactive protein increased</p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Upper respiratory tract infection (16%) </p><p><b>Common</b> (1% to 10%): Nasal congestion, rhinorrhea, rhinitis, sinusitis, pharyngitis, respiratory tract infection, tonsillitis</p><p id="ref_1">1. "Product Information. Trikafta (elexacaftor / ivacaftor / tezacaftor)." Vertex Pharmaceuticals, Cambridge, MA. </p><h2>More about elexacaftor / ivacaftor / tezacaftor</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>2 Reviews</li>
<li>Drug class: CFTR combinations</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Elexacaftor, tezacaftor, ivacaftor and ivacaftor &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Cystic Fibrosis</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>